Table 1.

Currently approved ICIs with their indications. (CTLA-4, cytotoxic T-lymphocyte-associated protein 4; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; FDA, Food and Drug Administration).

Drug	Target	Year of Approval (FDA)	Cancer/s
Atezolizumab	PD-L1	2016	Bladder cancer, breast cancer, liver cancer, lung cancer, and melanoma
Avelumab	PD-L1	2017	Bladder cancer, kidney cancer, and Merkel cell carcinoma
Cemiplimab	PD-1	2018	Squamous cell skin cancer
Dostarlimab	PD-1	2021	Endometrial cancer
Durvalumab	PD-1	2018	Lung cancer
Ipilimumab	CTLA-4	2011	Melanoma, mesothelioma, liver cancer, and lung cancer
Nivolumab	PD-1	2014	Bladder cancer, colorectal cancer, esophageal cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, lymphoma, melanoma, and mesothelioma
Pembrolizumab	PD-1	2014	Bladder cancer, breast cancer, cervical cancer, colorectal cancer, cutaneous squamous cell carcinoma, esophageal cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, lymphoma, melanoma, Merkel cell carcinoma, and stomach cancer